Cargando…

Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

BACKGROUND: Abnormal B-cell activation is implicated in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE). The B-cell surface molecule CD22, which regulates activation through the B-cell receptor (BCR), is a potential target for inhibiting pathogenic B cells; howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giltiay, Natalia V., Shu, Geraldine L., Shock, Anthony, Clark, Edward A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433084/ https://www.ncbi.nlm.nih.gov/pubmed/28506291 http://dx.doi.org/10.1186/s13075-017-1284-2

Ejemplares similares

Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells
por: Chang, Chien-Hsing, et al.
Publicado: (2014)

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
por: Daridon, Capucine, et al.
Publicado: (2010)

Toll-Like Receptor 7 (TLR7) Mediated Transcriptomic Changes on Human Mast Cells
por: Cho, Kyung-Ah, et al.
Publicado: (2021)

Interleukin-7 and Toll-Like Receptor 7 Induce Synergistic B Cell and T Cell Activation
por: Bikker, Angela, et al.
Publicado: (2014)

TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells
por: Suthers, Amy N., et al.
Publicado: (2017)

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients
por: Fleischer, Vanessa, et al.
Publicado: (2015)

Co-Stimulation of BCR and Toll-Like Receptor 7 Increases Somatic Hypermutation, Memory B Cell Formation, and Secondary Antibody Response to Protein Antigen
por: Castiblanco, Diana P., et al.
Publicado: (2017)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement
por: Lau, Christina M., et al.
Publicado: (2005)

Complement Receptor Type 1 (CR1, CD35), the Inhibitor of BCR-Mediated Human B Cell Activation, Differentially Regulates TLR7, and TLR9 Induced Responses
por: Mácsik-Valent, Bernadett, et al.
Publicado: (2019)

Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells
por: Giltiay, Natalia V., et al.
Publicado: (2013)

Necrotizing lymphadenitis may be induced by overexpression of Toll-like receptor7 (TLR7) caused by reduced TLR9 transport in plasmacytoid dendritic cells (PDCs)
por: Asano, Shigeyuki, et al.
Publicado: (2021)

The Local Activation of Toll-like Receptor 7 (TLR7) Modulates Colonic Epithelial Barrier Function in Rats
por: Estévez, Javier, et al.
Publicado: (2023)

Contrasted evolutionary histories of two Toll-like receptors (Tlr4 and Tlr7) in wild rodents (MURINAE)
por: Fornůsková, Alena, et al.
Publicado: (2013)

Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19
por: Khalifa, Amani E., et al.
Publicado: (2021)

Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells
por: Derkow, Katja, et al.
Publicado: (2013)

Toll-like Receptor 7 (TLR7) Is Expressed in Adipocytes and the Pharmacological TLR7 Agonist Imiquimod and Adipocyte-Derived Cell-Free Nucleic Acids (cfDNA) Regulate Adipocyte Function
por: Thomalla, Miriam, et al.
Publicado: (2022)

Precise determination of toll-like receptor (TLR) 7 expression in multiple human tumor types
por: Cumberbatch, Marie, et al.
Publicado: (2014)

CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
por: Clark, Edward A., et al.
Publicado: (2018)

Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus
por: Wen, Luyao, et al.
Publicado: (2023)

Pathway of Toll-Like Receptor 7/B Cell Activating Factor/B Cell Activating Factor Receptor Plays a Role in Immune Thrombocytopenia In Vivo
por: Yang, Qing, et al.
Publicado: (2011)

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2006)

The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome
por: Petes, Carlene, et al.
Publicado: (2017)

Structure of the Toll/Interleukin-1 Receptor (TIR) Domain of the B-cell Adaptor That Links Phosphoinositide Metabolism with the Negative Regulation of the Toll-like Receptor (TLR) Signalosome
por: Halabi, Samer, et al.
Publicado: (2017)

Classification, Mechanisms of Action, and Therapeutic Applications of Inhibitory Oligonucleotides for Toll-Like Receptors (TLR) 7 and 9
por: Lenert, Petar S.
Publicado: (2010)

Expression of Toll-Like Receptor -7 and -9 in B Cell Subsets from Patients with Primary Sjögren’s Syndrome
por: Karlsen, Marie, et al.
Publicado: (2015)

Toll‐Like Receptor (TLR)4 and MyD88 are Essential for Atheroprotection by Peritoneal B1a B Cells
por: Hosseini, Hamid, et al.
Publicado: (2016)

Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction
por: Uematsu, Satoshi, et al.
Publicado: (2005)

Clinical Implication of Toll-Like Receptors (TLR2 and TLR4) Polymorphisms in Adult Patients with Acute B-cell Lymphoblastic Leukemia
por: Aref, Salah, et al.
Publicado: (2022)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Expression of Toll-like receptor (TLR) 2, TLR3, TLR4 and TLR7 is increased in rheumatoid arthritis synovium and regulates cytokine production by dendritic cells upon stimulation of TLR specific pathways
por: Roelofs, MF, et al.
Publicado: (2005)

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Activation Toll-Like Receptor7 (TLR7) Responsiveness Associated with Mitogen- Activated Protein Kinase (MAPK) Activation in HIOEC Cell Line of Oral Squamous Cell Carcinoma
por: Mahmoud Hashemi, Ali, et al.
Publicado: (2018)

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
por: Al Rayes, Hanan, et al.
Publicado: (2014)

Influence of Age and Immunostimulation on the Level of Toll-Like Receptor Gene (TLR3, 4, and 7) Expression in Foals
por: Migdał, Anna, et al.
Publicado: (2020)

Carabin deficiency in B cells increases BCR-TLR9 costimulation-induced autoimmunity
por: Schickel, Jean-Nicolas, et al.
Publicado: (2012)

Identification and elucidation of cross talk between SLAM Family Member 7 (SLAMF7) and Toll-like receptor (TLR) pathways in monocytes and macrophages
por: Choe, Uyory, et al.
Publicado: (2023)

Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and function
por: Huang, Juan, et al.
Publicado: (2021)

Functional Effects of Toll-Like Receptor (TLR)3, 7, 9, RIG-I and MDA-5 Stimulation in Nasal Epithelial Cells
por: Tengroth, Lotta, et al.
Publicado: (2014)

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
por: Steinfeld, Serge D, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_i4n21t65oluq6mevkvacgqpdpt